Trial Profile
An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer's Disease.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Memantine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lundbeck A/S
- 10 Aug 2016 The trial was completed in Belgium.
- 31 May 2011 New trial record